Curis CRIS
NASDAQ CRIS
$1.24 +0.04 (+3.13%)
As of: Sep 10, 2026 · 10:37 AM EDT

Curis (CRIS) Non-Current Assets (2010 - 2026)

Curis' (CRIS) quarterly Non-Current Assets came in at $12.2 million in Q2 2026, down 17.34% on a YoY basis from $14.8 million in Q2 2025, and down 6.34% quarter-over-quarter from $13.1 million in Q1 2026.

Analysis

Curis (CRIS) Non-Current Assets (2010 - 2026) Analysis & Trends

Curis (CRIS) has reported Non-Current Assets for 17 consecutive years, with $12.2 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Non-Current Assets fell 17.34% year-over-year to $12.2 million; the trailing twelve-month figure through Jun 2026 stood at $52.1 million (down 12.79% YoY), and the FY2025 full-year result was $13.1 million, down 12.29% from the prior year.
  • Non-Current Assets fell to $12.2 million in Q2 2026 per CRIS's latest filing, from $13.1 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $17.1 million in Q3 2022 and bottomed at $12.2 million in Q2 2026.
  • Historically, Non-Current Assets has averaged $15.2 million across 5 years, with a median of $15.5 million in 2022.
  • The sharpest annual moves came in 2022 and 2023: Non-Current Assets sank 58.1% in 2022, then grew 13.25% in 2023.
  • Over 5 years, Non-Current Assets stood at $16.7 million in 2022, then fell by 2.12% to $16.4 million in 2023, then retreated by 9.12% to $14.9 million in 2024, then fell by 12.29% to $13.1 million in 2025, then decreased by 6.17% to $12.2 million in 2026.
  • According to Business Quant data, Non-Current Assets over the past three periods registered $12.2 million, $13.1 million, and $13.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Amgen 207.59 Bn 193.60 Bn 7.24 Bn 60.68 Bn
2 Gilead Sciences 178.73 Bn 175.55 Bn 6.22 Bn 35.42 Bn
3 Vertex Pharmaceuticals 131.17 Bn 123.32 Bn 2.84 Bn 14.88 Bn
4 Regeneron Pharmaceuticals 81.73 Bn 73.73 Bn 3.93 Bn 23.28 Bn
5 Argenx Se 61.01 Bn 55.82 Bn 1.37 Bn 1.96 Bn
6 Moderna 53.40 Bn 48.27 Bn 52.00 Mn 5.15 Bn
7 Alnylam Pharmaceuticals 33.49 Bn 30.18 Bn 992.69 Mn 938.60 Mn
8 Biogen 31.64 Bn 30.35 Bn 1.96 Bn 24.78 Bn
9 Roivant Sciences 29.66 Bn 29.66 Bn 1.16 Mn 564.41 Mn
10 Curis 2.64 Mn -2.97 Mn - 12.25 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 12.25 Mn
Mar 31, 2026 13.08 Mn
Dec 31, 2025 13.05 Mn
Sep 30, 2025 13.73 Mn
Jun 30, 2025 14.82 Mn
Mar 31, 2025 14.52 Mn
Dec 31, 2024 14.88 Mn
Sep 30, 2024 15.54 Mn
Jun 30, 2024 15.89 Mn
Mar 31, 2024 15.96 Mn
Dec 31, 2023 16.37 Mn
Sep 30, 2023 16.55 Mn
Jun 30, 2023 16.46 Mn
Mar 31, 2023 16.53 Mn
Dec 31, 2022 16.73 Mn
Sep 30, 2022 17.14 Mn
Jun 30, 2022 15.44 Mn
Mar 31, 2022 14.60 Mn
Dec 31, 2021 39.93 Mn
Sep 30, 2021 37.14 Mn